PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|February 26, 2020
Federal Equipment Company
Author(s)Federal Equipment Company
Federal Equipment Company is a reliable resource for pharmaceutical processing and packaging equipment needs, with over 60 years of expertise working with manufacturers seeking to buy and sell used equipment.
Federal Equipment Company buys and sells pharmaceutical manufacturing and processing equipment. The company's inventory includes equipment for the manufacture of pharmaceuticals, vitamins, nutraceuticals, supplements, ingredients, and food and beverage manufacturing. These machines are used to manufacture a variety of forms: solid dose (tablets, capsules, powders), semi-solid (creams, ointments, gels), liquid, aseptic fill and finish (vials, ampoules, prefilled syringes), transdermal patches, and more. If you can’t find the pharmaceutical equipment you’re looking for, contact our team and we’ll help match you to the machinery you need.
Federal Equipment Company
tel. +1.800.652.2466
sales@fedequip.com
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.